• Murtaza Sameen Junejo, RebeccaDr. Rebecca, MBBS. Department of Ophthalmology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan., Maria Nazish Memon, and Sajida Parveen Shaikh.
• Dr. Murtaza Sameen Junejo, FCPS. Department of Ophthalmology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
• Pak J Med Sci. 2021 Nov 1; 37 (7): 1935-1938.

ObjectiveTo observe efficacy of Timolol maleate 0.5% by topical and surface application in infantile superficial capillary hemangioma of eyelid.MethodsThis multi-centered clinical case series was carried out at Ophthalmology Department of Bilawal Medical College and Institute of Ophthalmology, LUMHS, Jamshoro from November 2019 to May 2020. We included 14 subjects. All the patients were subjected to detailed clinical examination. Before starting the topical beta blockers, the enrolled subjects had obtained the expert opinion by pediatrician to rule out any preexisting developmental cardio vascular disease. Topical beta blockers 0.5% drops were thus started with, against the ongoing finding of superficial capillary hemangioma of eyelid.ResultsThere was significant regression in size of infantile hemangioma after treating with topical timolol maleate 0.5%. We included 14 subjects in this study. Mean±SD age of patients was 4.94. Complete regression was seen in 08 subjects at the end of 12 weeks (64%) while 03 were completely cured at 08 weeks (21%) and 01 patient lost follow up with us. No significant ocular and systemic side effects were noted.ConclusionTopical timolol maleate 0.5% can be the first-line treatment modality for superficial capillary hemangiomas due to its better safety and efficacy.Copyright: © Pakistan Journal of Medical Sciences.

1 keywords...

hide…